Telum Therapeutics appoints Dr. Subhendu Basu as CEO

"I am truly inspired by Telum's cutting-edge science, its dynamic pipeline, and the team's accomplishments thus far," remarked Dr. Basu. "As CEO, I am eager to collaborate with the Telum scientific team and our dedicated investors to spur growth and advance Telum's investigational products into clinical trials for patient benefit." "I am truly inspired by Telum's cutting-edge science, its dynamic pipeline, and the team's accomplishments thus far," remarked Dr. Basu. "As CEO, I am eager to...

"I am truly inspired by Telum's cutting-edge science, its dynamic pipeline, and the team's accomplishments thus far," remarked Dr. Basu. "As CEO, I am eager to collaborate with the Telum scientific team and our dedicated investors to spur growth and advance Telum's investigational products into clinical trials for patient benefit."

In conjunction with Dr. Basu's joining, Roberto Díez-Martínez, PhD, the founding CEO, transitions to Chief Operating Officer. Under Dr. Díez-Martínez's guidance, Telum developed its proprietary APEX platform, yielding new antimicrobial agents derived from endolysins with broad-spectrum antibacterial efficacy, resistance prevention, and proven effectiveness in various Gram-negative infection models. Additionally, he has fortified the company's scientific leadership, expanded the Board and established a premier Scientific Advisory Board.

Reflecting on the transition, Dr. Díez-Martínez remarked, "After years of progress and technological breakthroughs at Telum, I warmly welcome Dr. Basu as the new CEO. I am confident that Dr. Basu's leadership, in concert with the Telum team, will drive significant scientific, technological, and clinical advancements, positioning Telum as a transformative force in infectious disease treatment through innovative technology like endolysin-based phage lysin enzyme platforms (EPLEs)."

Dr. Basu's vision for Telum Therapeutics involves ushering in a new development phase for its therapies, with a clear corporate strategy which will include a focus on advancing candidates to the clinic, expanding the portfolio of Telum's novel engineered lysins and establishing strategic partnerships to fully exploit the APEX platform's potential.

About Telum Therapeutics

Founded in Navarra in 2019, by Roberto Díez and Rubén Díez, Telum Therapeutics, S.L., is a global drug discovery biotechnology company that develops new treatments for infectious diseases based on the use of lytic enzymes from bacteriophages, called enzybiotics. In 2020, the company raised its first round of financing from Invivo Ventures, and the co-investment of Clave Capital and CDTI-Innvierte.

For enquiries contact: contact@telumtherapeutics.com 

Logo - https://mma.prnewswire.com/media/2365322/Telum_Therapeutics_Logo.jpg

View original content:https://www.prnewswire.co.uk/news-releases/telum-therapeutics-appoints-dr-subhendu-basu-as-ceo-302092418.html